Treatments for multiple myeloma (MM) are constantly evolving—bringing forward drugs with improved efficacy that lead to better patient outcomes. Immunotherapy agents such as bispecific antibodies (BsAbs) are the backbone of MM therapy, but continued ... [10919 chars].. reed more
